Why the study?
Limited clinical data exist on DOAC use in patients with BMI >40 kg/m 2 or weight >120 kg, making DOAC therapy in this population controversial.
Does rivaroxaban reduce clinical failure compared to warfarin in extremely obese or high-body-weight patients with atrial fibrillation or VTE?
Does rivaroxaban reduce clinical failure compared to warfarin in extremely obese or high-body-weight patients with atrial fibrillation or VTE?
In extremely obese or high-body-weight patients with AF or VTE, rivaroxaban was associated with a significantly shorter length of stay and a non-significant trend toward lower clinical failure compared to warfarin.
No takes yet. Share an insight, caveat, or question.
Rivaroxaban showed similar outcomes to warfarin; leaves open optimal DOAC use in extreme obesity pending randomized trials.
Perales et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: